SCHEMBL2955630

SCHEMBL2955630

C[C@@H](NC(C)(C)CO)C(=O)c1cccc(Cl)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2B6 P20813 1/20 1.00
SLC6A2 P23975 8/20 0.74
SLC6A3 Q01959 7/20 0.74
CHRNA1 P02708 5/20 0.74
CHRNG P07510 5/20 0.74
CHRNB1 P11230 5/20 0.74
CHRNB2 P17787 5/20 0.74
CHRNB4 P30926 5/20 0.74
CHRNA3 P32297 5/20 0.74
CHRNA4 P43681 5/20 0.74
CHRND Q07001 5/20 0.74
SLC6A4 P31645 4/20 0.74
ITGA5 P08648 1/20 0.74
CYP2C19 P33261 1/20 0.74
HRH1 P35367 1/20 0.74
CHRNA7 P36544 1/20 0.74
OPRK1 P41145 1/20 0.74
KCNH2 Q12809 1/20 0.74
ALDH1A1 P00352 2/20 0.72
BLM P54132 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1226857 1.00 CYP2B6 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
SCHEMBL29486913 1.00 CYP2B6 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
SCHEMBL2955633 1.00 CYP2B6 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
SCHEMBL29564521 0.91 CYP2B6 (0.83) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
SCHEMBL15478523 0.89 CYP2B6 (0.80) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
Bupropion SCHEMBL38777 0.85 SLC6A3 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
Bupropion SCHEMBL29354885 0.85 SLC6A3 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
Bupropion SCHEMBL29424575 0.85 SLC6A3 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
Bupropion SCHEMBL300444 0.85 SLC6A3 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG
Bupropion SCHEMBL12499296 0.85 SLC6A3 (1.00) CYP2B6SLC6A2SLC6A3CHRNA1CHRNG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311727-A1 THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS ALGEBRA, INC. (US) 2010-12-09 US claimed
US-7763612-B2 Therapeutic amine-arylsulfonamide conjugate compounds ALGEBRA, INC. (US) 2010-07-27 US claimed
EP-1259243-B2 BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE SEPRACOR INC (US) 2010-07-21 EP claimed
US-20070155729-A1 THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS ALGEBRA, INC. (US) 2007-07-05 US claimed
US-20100311727-A1 THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS ALGEBRA, INC. (US) 2010-12-09 US disclosed
US-7763612-B2 Therapeutic amine-arylsulfonamide conjugate compounds ALGEBRA, INC. (US) 2010-07-27 US disclosed
US-20100125070-A1 Bupropion Metabolites and Methods of Their Synthesis and Use FANG KEVIN QUN 2010-05-20 US disclosed
US-20070155729-A1 THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS ALGEBRA, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155729-A1 THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS AADAT, AADAC, AANAT CYP2B6 105/4885SLC6A2 49/4885SLC6A3 21/4885
US-20100125070-A1 Bupropion Metabolites and Methods of Their Synthesis and Use MAOB, MAOA, HTR5A CYP2B6 104/4885SLC6A2 6/4885SLC6A3 10/4885
US-20100311727-A1 THERAPEUTIC AMINE-ARYLSULFONAMIDE CONJUGATE COMPOUNDS AADAT, AADAC, AANAT CYP2B6 105/4885SLC6A2 49/4885SLC6A3 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.